Neoplasia: An International Journal for Oncology Research (Jun 2005)

Cas Ilgly Induces Apoptosis in Glioma C6 Cells In Vitro and In Vivo through Caspase-Dependent and Caspase-Independent Mechanisms

  • Cristina Trejo-Solís,
  • Guadalupe Palencia,
  • Sergio Zuñiga,
  • Andrea Rodríguez-Ropon,
  • Laura Osorio-Rico,
  • Sanchez Torres Luvia,
  • Isabel Gracia-Mora,
  • Lucrecia Marquez-Rosado,
  • Aurora Sánchez,
  • Miguel E. Moreno-García,
  • Arturo Cruz,
  • María Elena Bravo-Gómez,
  • Lena Ruiz-Ramírez,
  • Sara Rodríquez-Enriquez,
  • Julio Sotelo

DOI
https://doi.org/10.1593/neo.04607
Journal volume & issue
Vol. 7, no. 6
pp. 563 – 574

Abstract

Read online

In this work, we investigated the effects of Casiopeina Il-gly (Cas ILgly)—a new copper compound exhibiting antineoplastic activity—on glioma C6 cells under both in vitro and in vivo conditions, as an approach to identify potential therapeutic agents against malignant glioma. The exposure of C6 cells to Cas Ilgly significantly inhibited cell proliferation, increased reactive oxygen species (ROS) formation, and induced apoptosis in a dose-dependent manner. In cultured C6 cells, Cas Ilgly caused mitochondrio-nuclear translocation of apoptosis induction factor (AIF) and endonuclease G at all concentrations tested; in contrast, fragmentation of nucleosomal DNA, cytochrome c release, and caspase-3 activation were observed at high concentrations. Administration of N-acetyl-l-cystein, an antioxidant, resulted in significant inhibition of AIF translocation, nucleosomal DNA fragmentation, and caspase-3 activation induced by Cas Ilgly. These results suggest that caspase-dependent and caspase-independent pathways both participate in apoptotic events elicited by Cas Ilgly. ROS formation induced by Cas Ilgly might also be involved in the mitochondrio-nuclear translocation of AIF and apoptosis. In addition, treatment of glioma C6-positive rats with Cas Ilgly reduced tumor volume and mitotic and cell proliferation indexes, and increased apoptotic index. Our findings support the use of Cas Ilgly for the treatment of malignant gliomas.

Keywords